CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Treatment of multiple myeloma: What is the impact on T-cell function?
Treatment of multiple myeloma: What is the impact on T-cell function?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过去数十年，多发性骨髓瘤（MM）治疗取得显著进展。自体干细胞移植、蛋白酶体抑制剂、免疫调节药物及单克隆抗体已大幅改善患者预后。CAR-T（CAR-T）细胞、双特异性 T 细胞衔接器、抗体药物偶联物、组蛋白去乙酰化酶抑制剂和核输出抑制剂等新疗法带来了更多选择，但 MM 仍无法治愈。T 细胞是抗肿瘤免疫的主要武器，但 MM 患者的 T 细胞会出现多种功能障碍。靶向 T 细胞免疫疗法的临床效果令人鼓舞，凸显改善 T 细胞功能对骨髓瘤治疗的重要性。本综述总结这些抗骨髓瘤药物对 T 细胞功能的潜在影响，并讨论通过增强 T 细胞免疫优化 MM 管理的策略。
Treatment of multiple myeloma (MM) has evolved remarkably over the past few decades. Autologous stem cell transplantation, as well as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has substantially improved the prognosis of patients with MM. Novel therapies, including chimeric antigen receptor-T cells, bispecific T-cell engagers, antibody-drug conjugates, histone deacetylase inhibitors, and nuclear export inhibitors, have provided more options.
However, MM remains incurable. T cells are the principal weapons of antitumor immunity, but T cells display a broad spectrum of dysfunctional states during MM. The promising clinical results of T-cell-directed immunotherapies emphasize the significance of enhancing T-cell function in antimyeloma treatment. This review summarizes the potential effects of these antimyeloma agents on T-cell function and discusses possible optimized strategies for MM management by boosting T-cell immunity.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
